Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on July 14, 2025
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
GlobeNewswire
·
July 14, 2025
--Brian Hodous, Ph.D., promoted to chief scientific officer -- Vivek Kadambi, Ph.D., joins Recludix as senior vice president of non-clinical sciences and CMC -- Kristin Polsenski, M.B.A., expands role to include chief of staff to the CEO SAN DIEGO, July 14 …
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
GlobeNewswire
·
July 14, 2025
IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating the …
HYTN Secures Cannabis Drug Licence, Advancing Prescription Drug Pathway for Cannabinoid-Based Medicines
GlobeNewswire
·
July 14, 2025
VANCOUVER, British Columbia, July 14, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a leader in pharmaceutical-grade cannabis manufacturing, is pleased to announce it has received a …
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire
·
July 14, 2025
TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health …
Santé Canada étend l’approbation d’Evkeeza® (évinacumab) chez les enfants âgés d’à peine 6 mois atteints d’hypercholestérolémie familiale homozygote (HFHo)
GlobeNewswire
·
July 14, 2025
TORONTO, 14 juill. 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ : RARE), une société biopharmaceutique spécialisée dans la mise au point et la commercialisation de nouveaux traitements contre des maladies génétiques rares et très rares, …
Study: First Brain Fitness Tracker Validated for Aging Independently
GlobeNewswire
·
July 14, 2025
SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- A new study shows that a novel online assessment (here) provides a valid scientific measure of the cognitive abilities of older adults related to living independently. The self-administered assessment can be …
Gero Appoints Longevity Expert Dr. Brian Kennedy to Board of Directors
GlobeNewswire
·
July 14, 2025
SINGAPORE, July 14, 2025 (GLOBE NEWSWIRE) -- Gero, an AI-driven biotechnology company focused on developing therapeutics for age-related diseases, today announced the appointment of Brian Kennedy, Ph.D., to its Board of Directors. Dr. Kennedy is a globally …
Synergy CHC Corp. (NASDAQ: SNYR) Secures Retail Deals with McKesson Canada and Others as FOCUSfactor Expansion Surges Across North America
GlobeNewswire
·
July 14, 2025
WESTBROOK, Maine, July 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, today announced a new wave of retail and distribution wins across its FOCUSfactor …
Hydreight Technologies Signs Binding Letter of Intent to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
GlobeNewswire
·
July 14, 2025
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, July 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6),("Hydreight" or the "Company …
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
GlobeNewswire
·
July 14, 2025
SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced positive interim safety and efficacy results …
Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong
GlobeNewswire
·
July 14, 2025
FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong Intellectual …
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
GlobeNewswire
·
July 14, 2025
New “Decision to grant” communications in Canada and Israel For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage …
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
GlobeNewswire
·
July 14, 2025
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in rare genetic conditions – – Building and growing a …
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
GlobeNewswire
·
July 14, 2025
Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons’ needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to …
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
GlobeNewswire
·
July 14, 2025
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel …
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
GlobeNewswire
·
July 14, 2025
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical …
Kraig Biocraft Laboratories Announces Second Production Facility, Three Advanced Spider Silk Strains, and New Diapausing System
GlobeNewswire
·
July 14, 2025
ANN ARBOR, Mich., July 14, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig”, or "Kraig Labs"), a world leader in spider silk technology*, announces the addition of a second parallel production facility, three new …
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
GlobeNewswire
·
July 14, 2025
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference …
Personal Health Data Finally Simplified: Meet Validic Sparks
GlobeNewswire
·
July 14, 2025
DURHAM, N.C., July 14, 2025 (GLOBE NEWSWIRE) -- Validic, the platform for Connected Health Data and remote patient monitoring (RPM), today announced the launch of Validic Sparks, a generative AI solution designed to help healthcare organizations transform …
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
GlobeNewswire
·
July 14, 2025
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter …